The use of bazedoxifene is reserved for postmenopausal women. When used alone, the active principle is used for the treatment of osteoporosis in this category of patients; when used in combination with conjugated estrogens, however, bazedoxifene is used as a drug to relieve postmenopausal symptoms.
On the market, there are two medicines containing the active ingredient: one based on bazedoxifene only with the trade name Conbriza® and one containing the active ingredient associated with conjugated estrogens and with the trade name Duavive®. Both can be dispensed upon presentation of a repeatable medical prescription; however, the former is classified as a group A drug and, where applicable, can be dispensed at the expense of the National Health System (NHS); while the second is classified as a class C drug, therefore, its cost is fully borne by the citizen.
